Spyre Therapeutics
SYRE
54 hedge funds and large institutions have $601M invested in Spyre Therapeutics in 2023 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 4 closing their positions.
1,270% more capital invested
Capital invested by funds: $43.9M → $601M (+$557M)
625% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 4
603.32% more ownership
Funds ownership: 88.31% → 691.63% (+603%)
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
86% more funds holding
Funds holding: 29 → 54 (+25)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$52.2M |
| 2 |
PA
Perceptive Advisors
New York
|
+$34.8M |
| 3 |
RI
RTW Investments
New York
|
+$30.8M |
| 4 |
VA
VR Adviser
New York
|
+$28.6M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$26.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.67M |
| 2 |
ACM
Aisling Capital Management
New York
|
-$829K |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$827K |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$399K |
| 5 |
YF
Yu Fan
|
-$348K |
SYRE Hedge Fund Activity: Q4 2023 in Review
54 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q4 2023, worth a combined $601M — up 1,270% from $43.9M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new SYRE positions and 4 closed out — a net gain of 25 holders — while 15 added to existing stakes and 6 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $52.2M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $1.67M sold.
- 54 institutional investors held Spyre Therapeutics (SYRE) as of Q4 2023, up from 29 in Q3 2023.
- Funds reported $601M of Spyre Therapeutics stock for Q4 2023, up 1,270% quarter-over-quarter.
- 29 funds opened new Spyre Therapeutics positions in Q4 2023 and 4 closed out, a net change of +25 holders.
- The largest Spyre Therapeutics buyer in Q4 2023 was Fidelity Investments, an estimated $52.2M added.
- The largest Spyre Therapeutics seller in Q4 2023 was Rock Springs Capital Management, an estimated $1.67M sold.
Based on aggregated 13F filings for Q4 2023.